drugset / Trial / NCT00981617

ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence

NCT00981617

Phase 2 Completed 406 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety and efficacy of ALKS33 (RDC-0313) compared with placebo in adults with alcohol dependence. There will be 11 study visits conducted over a period of about 4 months. The study period includes a screening visit, a 12-week treatment period, and a follow-up visit.

Timeline

Start
2009-10
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Samidorphan Small molecule 1 mg Oral
Subject Samidorphan Small molecule 2.5 mg Oral
Subject Samidorphan Small molecule 10 mg Oral

Indications